196 related articles for article (PubMed ID: 21307149)
1. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
Clin Cancer Res; 2011 May; 17(10):3293-303. PubMed ID: 21307149
[TBL] [Abstract][Full Text] [Related]
2. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
[TBL] [Abstract][Full Text] [Related]
3. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
[TBL] [Abstract][Full Text] [Related]
4. GUCY2C molecular staging personalizes colorectal cancer patient management.
Gong JP; Schulz S; Hyslop T; Waldman SA
Biomark Med; 2012 Jun; 6(3):339-48. PubMed ID: 22731908
[TBL] [Abstract][Full Text] [Related]
5. Molecular staging estimates occult tumor burden in colorectal cancer.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
Adv Clin Chem; 2010; 52():19-39. PubMed ID: 21275338
[TBL] [Abstract][Full Text] [Related]
6. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.
Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
J Surg Oncol; 2012 Jul; 106(1):24-30. PubMed ID: 22252429
[TBL] [Abstract][Full Text] [Related]
7. Does stage II colorectal cancer need to be redefined?
Grothey A
Clin Cancer Res; 2011 May; 17(10):3053-5. PubMed ID: 21498396
[TBL] [Abstract][Full Text] [Related]
8. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
Cancer; 2012 May; 118(9):2532-40. PubMed ID: 21887684
[TBL] [Abstract][Full Text] [Related]
9. Guanylyl cyclase C as a biomarker in colorectal cancer.
Hyslop T; Waldman SA
Biomark Med; 2013 Feb; 7(1):159-67. PubMed ID: 23387497
[TBL] [Abstract][Full Text] [Related]
10. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
Cagir B; Gelmann A; Park J; Fava T; Tankelevitch A; Bittner EW; Weaver EJ; Palazzo JP; Weinberg D; Fry RD; Waldman SA
Ann Intern Med; 1999 Dec; 131(11):805-12. PubMed ID: 10610624
[TBL] [Abstract][Full Text] [Related]
11. Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study.
Chen G; McIver CM; Texler M; Lloyd JM; Rieger N; Hewett PJ; Sen Wan D; Hardingham JE
Dis Colon Rectum; 2004 May; 47(5):679-86. PubMed ID: 15037935
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients.
Conzelmann M; Dieterle CP; Linnemann U; Berger MR
Int J Cancer; 2003 Nov; 107(4):617-28. PubMed ID: 14520701
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
[TBL] [Abstract][Full Text] [Related]
14. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
Waldman SA; Cagir B; Rakinic J; Fry RD; Goldstein SD; Isenberg G; Barber M; Biswas S; Minimo C; Palazzo J; Park PK; Weinberg D
Dis Colon Rectum; 1998 Mar; 41(3):310-5. PubMed ID: 9514425
[TBL] [Abstract][Full Text] [Related]
15. Molecular staging individualizing cancer management.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
J Surg Oncol; 2012 Apr; 105(5):468-74. PubMed ID: 22441898
[TBL] [Abstract][Full Text] [Related]
16. Molecular staging of node negative patients with colorectal cancer.
Hyslop T; Waldman SA
J Cancer; 2013; 4(3):193-9. PubMed ID: 23459453
[TBL] [Abstract][Full Text] [Related]
17. Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.
Carlson MR
Mol Diagn Ther; 2009; 13(1):11-4. PubMed ID: 19351210
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.
Gill S; Haince JF; Shi Q; Pavey ES; Beaudry G; Sargent DJ; Fradet Y
Clin Colorectal Cancer; 2015 Jun; 14(2):99-105. PubMed ID: 25619805
[TBL] [Abstract][Full Text] [Related]
19. Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study.
Sargent DJ; Shi Q; Gill S; Louvet C; Everson RB; Kellner U; Clancy TE; Pipas JM; Resnick MB; Meyers MO; Wu TT; Huntsman D; Validire P; Farooq U; Pavey ES; Beaudry G; Haince JF; Fradet Y
Clin Cancer Res; 2014 Aug; 20(16):4361-9. PubMed ID: 24919572
[TBL] [Abstract][Full Text] [Related]
20. Lymph node CXCL17 messenger RNA: A new prognostic biomarker for colon cancer.
Rashad Y; Olsson L; Israelsson A; Öberg Å; Lindmark G; Hammarström ML; Hammarström S; Sitohy B
Tumour Biol; 2018 Sep; 40(9):1010428318799251. PubMed ID: 30198422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
